GSK

Business Context and Reporting Period

Company: GSK Plc
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: Quarter ended 30 September 2017 (Q3) and Nine Months ended 30 September 2017.
Issued Date: 25 October 2017

GSK reported continued progress in sales growth and improved operating margins, driven by targeted cost savings, restructuring benefits, and strong performance in new products. The company maintains its full-year 2017 Adjusted EPS growth guidance of 3% to 5% on a Constant Exchange Rate (CER) basis.

Key Financial Metrics

Segment Performance (Q3 2017):

• Pharmaceuticals: £4.2 billion (+3% AER, +2% CER). Margin 34.0%.
• Vaccines: £1.7 billion (+5% AER, flat CER). Margin 41.3%.
• Consumer Healthcare: £2.0 billion (+5% AER, +2% CER). Margin 20.0%.

Material Changes vs. Prior Period

• Revenue Growth: Group turnover increased 4% at Actual Exchange Rates (AER) and 2% at Constant Exchange Rates (CER) in Q3. Growth was driven by Pharmaceuticals and Consumer Healthcare, while Vaccines were flat at CER due to competitive pressures and shipment phasing reversals.
• Profitability: Total operating margin improved to 23.9% (+4.9 points) and Adjusted operating margin to 31.5% (+1.0 point). This was primarily due to reduced transaction-related charges (re-measurement of contingent consideration and put options) compared to Q3 2016, alongside cost savings and restructuring benefits.
• EPS Impact: Total EPS rose 49% AER, largely reflecting the significant reduction in transaction-related accounting charges compared to the prior year. Adjusted EPS was flat at CER (+3% AER).
• Divestments: Recent divestments (e.g., Nigerian beverages, Romanian distribution, thrombosis/anaesthesia businesses) negatively impacted growth in specific segments and regions.

Guidance, Outlook, and Risks

Guidance: GSK maintains its 2017 Adjusted EPS growth guidance of 3% to 5% on a CER basis. The company expects to pay an annual ordinary dividend of 80p for 2017.

Management Commentary: CEO Emma Walmsley highlighted continued progress in sales and margins, driven by cost savings and investment in the R&D pipeline. Major approvals for Trelegy Ellipta (COPD) and Shingrix (shingles vaccine) were secured.

Risks and Contingencies:

• Legal Matters: The Group is involved in significant legal proceedings (product liability, IP, tax, anti-trust). Aggregate provision for legal disputes was £0.2 billion as of 30 September 2017. Ultimate liability may vary.
• Contingent Consideration: Significant liabilities exist for contingent consideration related to ViiV Healthcare (Shionogi) and Vaccines (Novartis) acquisitions, as well as put options. These are subject to re-measurement based on trading forecasts and exchange rates.
• Patent Expirations: Continued decline in sales of Seretide/Advair is expected. The outlook assumes no premature loss of exclusivity for other key products.
• Exchange Rates: Results are sensitive to currency fluctuations. A weaker Sterling provided a positive currency benefit in the reported period.

Investor Verification Checklist

• Adjusted vs. Total Results: Verify the reconciliation between Total and Adjusted results, specifically the magnitude of transaction-related charges (£40m in Q3 2017 vs £799m in Q3 2016) which significantly inflated Total EPS growth.
• Contingent Consideration Liability: Review the balance sheet exposure to contingent consideration (£5.9 billion total) and put options, noting the sensitivity to exchange rates and trading forecasts.
• Advair/Seretide Decline: Monitor the rate of decline in legacy respiratory products (Advair/Seretide) as the company transitions to new Ellipta portfolio products.
• Free Cash Flow Conversion: Assess the sustainability of free cash flow generation (£1.6bn YTD) against dividend commitments (£2.977bn paid YTD) and net debt levels (£14.2bn).
• Regulatory Approvals: Confirm the commercial launch timelines and uptake for newly approved products Trelegy Ellipta and Shingrix.